Tobacco smoking and the risk of Parkinson disease

A 65-year follow-up of 30,000 male British doctors

Benjamin Mappin-Kasirer, MSc,* Hongchao Pan, DPhil,* Sarah Lewington, DPhil, Jennifer Kizza, MSc, Richard Gray, DPhil, Robert Clarke, FRCP,∗ and Richard Peto, FRS*

Neurology® 2020;94:e2132-e2138. doi:10.1212/WNL.0000000000009437

Abstract

Objective

To investigate the causal relevance of current tobacco smoking for the risk of Parkinson disease (PD).

Methods

We compared the risks of death from PD with smoking habits in 30,000 male doctors in the British Doctors cohort study in 1951 and in survivors who had been resurveyed periodically for 5 decades. Cause-specific mortality was monitored for 65 years and included 283 deaths from PD. The relative risks (RRs) of PD (and 95% confidence intervals [CIs]) were estimated using Cox models for smoking habits (smoking status, amount smoked, and years since quitting) at baseline or updated habits at resurvey.

Results

The prevalence of current smoking declined progressively during follow-up from 67% to 8% between 1951 and 1998. The crude rates of PD death were lower in current smokers than in never smokers at baseline (30 vs 46/100,000 persons-years). After adjustment for age at risk, current smokers at baseline had a 30% lower risk of PD (RR 0.71; 95% CI 0.60–0.84), and continuing smokers classified using updated smoking habits at resurvey had a 40% lower risk (RR 0.60; 95% CI 0.46–0.77) of PD compared with never smokers. The risks of PD were inversely associated with the amount of tobacco smoked. The protective effect of current smoking vs never smoking for PD was attenuated by increasing duration since quitting smoking.

Conclusions

In contrast to previous suggestions, the present report demonstrates a causally protective effect of current smoking on the risk of PD, which may provide insights into the etiology of PD.

*These authors contributed equally to this work.

From the Clinical Trial Service Unit and Epidemiological Studies Unit (B.M.-K., H.P., S.L., J.K., R.G., R.C., R.P.), Nuffield Department of Population Health, University of Oxford; and Medical Research Council Population Health Research Unit (H.P., S.L.), Nuffield Department of Population Health, University of Oxford, United Kingdom.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the Research Councils of the United Kingdom.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tobacco is a major cause of premature deaths in high-, middle-, and low-income countries, accounting for approximately 100 million deaths in the 20th century and a predicted 1 billion deaths in the 21st century.1–6 In the 50-year follow-up of male British doctors, current cigarette smoking caused more deaths from vascular, respiratory, and other neoplastic diseases than from lung cancer alone.6–11 The risks of almost all non-communicable diseases (ischemic heart disease, cerebrovascular disease, diabetes, chronic lung disease, pneumonia, cirrhosis of the liver, and cancers of the mouth, esophagus, lung, and pancreas) were found to be higher in current smokers than in nonsmokers,4–6 except for Parkinson disease (PD), which is reported to be inversely associated with smoking.11,12

PD is a progressive neurodegenerative disorder characterized by clinical symptoms of bradykinesia, resting tremor, and muscular rigidity. Nonmotor symptoms of PD, including olfactory dysfunction, constipation, disordered sleep, and disordered mood, may precede the onset of motor symptoms by about a decade.13–15 The etiology of PD is poorly understood, but the pathology includes accumulation of Lewy bodies and loss of dopaminergic neurons in the substantia nigra region of the basal ganglia.13,14 PD is the most common movement disorder and the second most common neurodegenerative disease worldwide, affecting approximately 6.1 million people in 2015 and predicted to affect 9 million by 2030.16,17 Little is known about the modifiable risk factors for PD, but previous studies have reported positive associations of PD with head injury, pesticide exposure, and consumption of dairy products and inverse associations with caffeine, serum urate, physical activity, ibuprofen, and tobacco smoking.18

A meta-analysis of observational studies reported that current smoking was associated with a 60% lower risk of PD (relative risk [RR] 0.42; 95% confidence interval [CI] 0.38–0.47).12 However, there is substantial uncertainty about the causal relevance of this inverse association. A recent large case-control study, involving 1,808 PD cases and 1,876 controls in Denmark, suggested that the lower risk of PD in current smokers was an artifact of reverse causality bias, whereby early nonmotor signs of PD may include a reduced response to nicotine stimulation, prompting current smokers to quit smoking before the diagnosis of PD can be made.19 Most previous studies of smoking and the risk of PD have used a retrospective case-control study design (in which information on smoking habits was collected after the onset of disease), and such studies are particularly susceptible to the effects of reverse causality bias. Several prospective studies11,12,20–22 have also reported inverse associations of smoking with PD, but few such studies have included a sufficient number of PD cases or involved an adequate duration of follow-up to exclude effects of reverse causality bias. The aims of the present report, involving analyses of the 65-year follow-up of 30,000 male British doctors, were to assess the risks of PD associated with tobacco smoking habits, amount of tobacco smoked, and effects of duration since quitting smoking among ex-smokers.

Methods

Standard protocol approvals, registrations, and patient consents

No relevant research ethics committees existed in 1951, when the British Doctors Study was designed and baseline questionnaires were sent. Doctors who chose to answer the first questionnaire were informed by investigators of the implications and methods of the study. Participants could choose to withdraw at any stage during follow-up, and all data were kept confidential.

Population

In 1951, all doctors who were registered with the British Medical Association and who were living in the United Kingdom were sent a postal questionnaire. Among 59,600 doctors contacted, two-thirds replied, and 34,439 (58.8%) male doctors provided complete data on their smoking habits. Surviving participants were resurveyed about changes in their smoking habits on 6 successive occasions between 1958 and 1998. Cause-specific mortality was monitored until November 30, 2016.

Smoking habits

Information on smoking habits for each participant was collected using 7 self-completed postal questionnaires.6–11 Doctors classified themselves as current tobacco smokers, ex-smokers, or never smokers. Current smokers were further questioned about the age at which they started smoking, the amount of tobacco they smoked daily, and the type of tobacco smoked (cigarette or pipe). Ex-smokers were asked the same questions about the time at which they last smoked and were asked about quitting smoking. Never smokers were those doctors having never consumed as much as 1 cigarette per day, or the equivalent in pipe or cigar tobacco, for as long as 1 year. Resurvey questionnaires presented participants with their answers to the previous questionnaire and asked whether their habits had changed. Questionnaires were not sent to participants who had previously refused to answer questions, those who asked not to be contacted again, or those who had been struck off the medical register. After reminders, response rates to the 6 resurveys varied between 94% and 98%.

Cigarette, pipe, and cigar smokers were combined as tobacco smokers for all analyses. No exclusions were made on the basis...
Strategies to minimize reverse causality bias

The impact of reverse causality bias in observational studies can be minimized by ensuring that information about exposures is collected before the onset of the disease; excluding participants with previous disease at enrollment; and excluding a relevant period of early follow-up to minimize distortion of results by cases of disease that were undetected at enrollment. Hence, the first 10 years of follow-up were excluded from all analyses to minimize the effects of reverse causality bias.

Statistical methods

Two statistical models were used to investigate the associations of tobacco smoking with the risk of PD. First, a Cox proportional hazards model assessed the effect of smoking habits at baseline in 1951 (hereafter, the “baseline model”). Second, a Cox proportional hazards model assessed the effect of smoking habits updated periodically after each resurvey questionnaire (hereafter, the “updated model”). However, updates in smoking habits took effect in the model only 10 years after they were reported to ensure that changes in habits were not caused by underlying disease.

RRs of PD (RR, approximated by hazard ratios) were estimated for (1) current and ex-smokers relative to never smokers; (2) current smokers of 1–14 and 15 or more cigarettes/day compared with never smokers; and (3) doctors not having smoked for 0–9 and 10 or more years compared with never smokers, after controlling for age at risk. RRs were adjusted for age at risk (i.e., current age during follow-up) rather than age at baseline to account for the

Table Characteristics of study participants at baseline and at resurveys

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of participants*—n (%)</td>
<td>29,737 (100)</td>
<td>29,737 (100)</td>
<td>27,617 (100)</td>
<td>24,800 (100)</td>
<td>18,515 (100)</td>
<td>12,146 (100)</td>
<td>7,919 (100)</td>
</tr>
<tr>
<td>Age, y—mean (SD)</td>
<td>41.9 (12.6)</td>
<td>48.9 (12.6)</td>
<td>55.6 (11.6)</td>
<td>59.1 (10.4)</td>
<td>64.6 (9.1)</td>
<td>73.3 (7.1)</td>
<td>79.1 (5.8)</td>
</tr>
<tr>
<td>Smoking status—n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>5,319 (17.9)</td>
<td>5,114 (17.2)</td>
<td>4,799 (17.4)</td>
<td>4,465 (18.0)</td>
<td>3,319 (17.9)</td>
<td>2,501 (20.6)</td>
<td>1,842 (23.2)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>4,446 (14.9)</td>
<td>8,027 (27.0)</td>
<td>9,994 (36.2)</td>
<td>10,307 (41.6)</td>
<td>10,545 (57.0)</td>
<td>7,688 (63.3)</td>
<td>5,415 (68.4)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>19,972 (67.2)</td>
<td>16,595 (55.8)</td>
<td>12,824 (46.4)</td>
<td>10,028 (40.4)</td>
<td>4,651 (25.1)</td>
<td>1,957 (16.1)</td>
<td>662 (8.4)</td>
</tr>
<tr>
<td>Daily amount smokedb—n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 cigarettes/d (never smoker)</td>
<td>5,319 (17.9)</td>
<td>5,114 (17.2)</td>
<td>4,799 (17.4)</td>
<td>4,465 (18.0)</td>
<td>3,319 (17.9)</td>
<td>2,501 (20.6)</td>
<td>1,842 (23.2)</td>
</tr>
<tr>
<td>&lt;15 cigarettes/d</td>
<td>8,205 (27.6)</td>
<td>7,469 (25.1)</td>
<td>6,363 (23.0)</td>
<td>5,658 (22.8)</td>
<td>2,715 (14.7)</td>
<td>1,235 (10.2)</td>
<td>466 (5.9)</td>
</tr>
<tr>
<td>15+ cigarettes/d</td>
<td>11,767 (39.6)</td>
<td>9,127 (30.7)</td>
<td>6,462 (23.4)</td>
<td>4,370 (17.6)</td>
<td>1,936 (10.5)</td>
<td>722 (5.9)</td>
<td>196 (2.5)</td>
</tr>
<tr>
<td>Time since last smokedc—n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quit, 10+ y ago</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3,356 (12.2)</td>
<td>7,703 (31.1)</td>
<td>5,596 (30.2)</td>
<td>6,059 (49.9)</td>
<td>3,836 (48.5)</td>
</tr>
<tr>
<td>Quit, &gt;0–9 y ago</td>
<td>4,446 (14.9)</td>
<td>8,027 (27.0)</td>
<td>6,638 (24.0)</td>
<td>2,604 (10.5)</td>
<td>4,949 (26.8)</td>
<td>1,629 (13.4)</td>
<td>1,579 (19.9)</td>
</tr>
<tr>
<td>Current smoker, 0 y</td>
<td>19,972 (67.2)</td>
<td>16,595 (55.8)</td>
<td>12,824 (46.4)</td>
<td>10,028 (40.4)</td>
<td>4,651 (25.1)</td>
<td>1,957 (16.1)</td>
<td>662 (8.4)</td>
</tr>
</tbody>
</table>

All percent values represent the fraction of surviving participants in the relevant survey.

*All analyses exclude the first 10 years of follow-up and participants who died during these 10 years.

b Cigarettes per day or equivalent in pipe and cigar tobacco: 1 cigar = 5 cigarettes, 1 small cigar = 3 cigarettes, 1 very small cigar = 1 cigarette, and 1 oz of tobacco per week = 4 cigarettes per day.

c Time since last smoked assessed prospectively during follow-up. Analyses assume that ex-smokers at baseline have just quit.
increasing risk of PD associated with increasing age during the follow-up period. Group-specific CIs were calculated for RRs.27,28 Tests for trends in PD risk across categories of daily amount of tobacco smoked and time elapsed since cessation were conducted using likelihood ratio tests. Analyses were conducted using STATA 14.2 (StataCorp, USA), and figures were plotted using R 3.4.1 (R Foundation, Austria). All statistical tests were 2 sided, and statistical significance was defined as $p < 0.05$.

Patient and public involvement
Participants were not involved in the design, conduct, analysis, or interpretation of the study. Results were disseminated by publications in medical journals and by the study website (cts.u.ox.ac.uk/research/british-doctors-study).

Data availability
No additional data are available.

Results
Baseline characteristics of the study population
Among 34,439 male doctors recruited in 1951, 467 (1.4%) requested no further questionnaires (mostly due to old age), 17 (0.05%) were excluded from the medical register (for professional misconduct), and follow-up was discontinued for 2,459 participants (7.1%) who were known to be alive but no longer living in the United Kingdom in 1971, leaving 29,737 (86.3%) male doctors for inclusion in the present analyses after exclusion of the first 10 years of follow-up (table). Figure 1 shows the decline in the prevalence of tobacco smoking in surviving doctors by age and survey year from 1951 to 1998. In doctors aged 65–69 years, the prevalence of current smoking declined from 67% in 1951 to 8% in 1998. The proportion of smokers who were cigarette smokers also declined from 63% in 1951 to 33% in 1998.

Smoking status and the risk of PD
From 1951 to 2016, participants were followed on average for 35 years (range: 11–65 years). Excluding the first 10 years of follow-up, 25,379 deaths were reported during 743,920 person-years. Among these, 283 (1.1%) had PD listed as their underlying cause of death. After classification of smoking habits at baseline, the crude death rate from PD was lower in current vs nonsmokers (30 vs 46 per 100,000 person-years; unadjusted RR reduction of 34.7%). Doctors who died of PD were followed on average for 42 years and had a mean age at death of 82 years, whereas those who died of causes other than PD were followed on average for 35 years and had a mean age of death of 77 years.

Current tobacco smoking was inversely associated with the risk of PD in both the baseline ($p = 0.006$) and updated ($p = 0.003$) models (figure 2). In the baseline model, doctors who reported current tobacco smoking in 1951 had about a 30% lower risk of PD compared with those who had never smoked on recruitment into the study (RR 0.71; 95% CI 0.60–0.84). In the updated model, current smokers had a 40% lower risk of PD compared with never smokers (RR 0.60; 95% CI 0.46–0.77).

Mean daily amount smoked and the risk of PD
Analysis of the smoking habits of current smokers suggested that there was an inverse dose-response relationship between the daily amount of tobacco smoked and the risk of PD. Adjusting for age at risk, the association between daily amount smoked and PD risk was statistically significant in both the baseline ($p = 0.0006$) and updated ($p = 0.002$) models (figure 3).

Duration since quitting smoking and the risk of PD
The risks of PD were estimated for ex- vs never smokers, and in the updated model, by the duration of time elapsed since quitting smoking (10 or more vs 0–9 years ago). Controlling for age at risk, duration since quitting was also associated with the risk of PD (figure 2). Compared with never smokers, those who quit smoking 10 or more years ago had a 14% lower risk of PD (RR 0.86; 95% CI 0.70–1.06), whereas those who quit 0–9 years ago had a 29% lower risk (RR 0.71; CI 0.54–0.93).
Discussion

This study of 30,000 male British doctors, which minimized the risk of reverse causality by having very prolonged follow-up, demonstrated an inverse association of current tobacco smoking with the risk of PD. Compared with never smoking, current tobacco smoking was associated with a 30% lower risk of PD using smoking habits at baseline and with a 40% lower risk using smoking habits that were updated at sequential surveys. The risk of PD was inversely related to the amount smoked, and the protective effect of smoking on the risk of PD was attenuated with increasing duration of time since quitting smoking.

The chief strengths of this study include the prolonged duration of follow-up, serial resurveys of smoking habits in each decade over 5 decades, and the consistently high response rates to each survey. Furthermore, the present study compared the effects of smoking on PD using 2 statistical models that took account of changes in smoking habits, reverse causality, and age at risk of PD, each of which yielded consistent results.

A limitation of this report was that the analyses were based on only 283 PD cases. Participants included only male British doctors, and the brief survey questionnaires that yielded high response rates did not collect data on the family history of PD, caffeine intake, or other covariates. However, results of the present study are consistent with those from previous Western population–based cohorts involving both men and women that also included extensive multivariate adjustment. Nonetheless, studies correcting for reverse causality bias in non–Western populations, with adjustment for other major risk factors for PD, could confirm the generalizability of these findings. In addition, cases with PD as the associated (secondary) cause of death were not considered. It is possible that the association of tobacco smoking with PD as the associated cause of death might differ from that of smoking with PD as the underlying cause of death, particularly if concomitant disease in the former was related to smoking. However,
the concordant results of the present report with those of previous prospective studies that included incident nonfatal PD cases suggest that any bias from relying on fatal cases where PD was the underlying cause of death is likely to be small. Furthermore, cases were defined using ICD codes for PD, which may not always account for distinction between primary PD and parkinsonism secondary to an unknown cause or between different clinical subtypes of PD. However, cases with PD as the underlying cause of death on death certificates were more likely to have more severe disease and more definite diagnoses of PD.39

The present analyses addressed concerns that the inverse associations observed between tobacco smoking and PD risk were an artifact of chance or bias. Even if the pathogenesis of PD begins 2 decades before the first motor manifestation of illness, smoking habits at baseline in 1951 would have been largely unaffected by premanifest disease, as they were recorded on average 42 years before death from PD and approximately 35 years before death from other causes. Hence, the protective effects of current smoking for PD are unlikely to be due to reverse causality bias. Because smoking is positively associated with many other causes of death, analyses that take account of competing risks would reduce the estimated death rate of PD to a greater extent in smokers than in nonsmokers. This, in turn, would tend to strengthen the inverse association of smoking with the risk of PD rather than dilute it.

The mechanisms underlying the inverse association between tobacco smoking and PD are not fully understood. Some studies have suggested that nicotine may have neuroprotective properties and stimulate the release of dopamine, but effects of other components of tobacco cannot be excluded.30,31 Recent studies have identified pathologic proteins in the nasal cavity and gut,32,33 and other studies have linked PD with derangements in lysosomal storage function.34 Given the effect of tobacco smoking on nasal and gut mucosa, it is possible that the inverse association of smoking with PD may be mediated by such mechanisms. Genome-wide association studies have identified genetic variants associated with PD risk35,36 and with particular smoking habits37 and provided some support for a causal relation between smoking habits and PD, albeit such studies have not yet elucidated the underlying mechanism.38

In all populations, the adverse effects of smoking on risks of vascular and respiratory diseases, neoplasms, and other noncommunicable diseases for which tobacco is the chief risk factor greatly exceed any protective effect of current tobacco smoking on the risk of PD. A trial of transdermal nicotine treatment to slow the progression of PD is currently underway (NCT01560754), but trials of primary prevention of PD are unlikely to be feasible. Nonetheless, the results of the present study suggest that efforts to characterize the biological mechanisms underlying the inverse association between tobacco and PD may be worthwhile and may contribute to a better etiologic understanding of PD.

Acknowledgment
Contributors Richard Doll (University of Oxford) and Austin Bradford Hill (London School of Hygiene and Tropical Medicine) designed the study in 1951.

Study funding
The Medical Research Council has supported the study since 1951 and continues to do so by supporting the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, with the British Heart Foundation and Cancer Research UK. The sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of data; or in the preparation and review of this manuscript.

Disclosure
The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Publication history
Received by Neurology June 24, 2019. Accepted in final form December 5, 2019.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Mappin-Kasirer, MSc</td>
<td>University of Oxford, United Kingdom</td>
<td>Planned and conducted the present analyses; wrote the first draft of the report; guarantor for the present analyses; and approved the final version</td>
</tr>
<tr>
<td>Hongchao Pan, DPhil</td>
<td>University of Oxford, United Kingdom</td>
<td>Planned and conducted the present analyses; guarantor for the present analyses; and approved the final version</td>
</tr>
<tr>
<td>Sarah Lewington, DPhil</td>
<td>University of Oxford, United Kingdom</td>
<td>Planned and conducted the present analyses; wrote the first draft of the report; and approved the final version</td>
</tr>
<tr>
<td>Jennifer Kizza, MSc</td>
<td>University of Oxford, United Kingdom</td>
<td>Wrote the first draft of the report and approved the final version</td>
</tr>
<tr>
<td>Richard Gray, DPhil</td>
<td>University of Oxford, United Kingdom</td>
<td>Worked on the study for almost 50 years and approved the final version</td>
</tr>
<tr>
<td>Robert Clarke, FRCP</td>
<td>University of Oxford, United Kingdom</td>
<td>Planned and conducted the present analyses; wrote the first draft of the report; and approved the final version</td>
</tr>
<tr>
<td>Richard Peto, FRS</td>
<td>University of Oxford, United Kingdom</td>
<td>Worked on the study for almost 50 years and approved the final version</td>
</tr>
</tbody>
</table>

References
Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors
Benjamin Mappin-Kasirer, Hongchao Pan, Sarah Lewington, et al.

*Neurology* 2020;94:e2132-e2138 Published Online before print May 5, 2020
DOI 10.1212/WNL.0000000000009437

This information is current as of May 5, 2020

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/94/20/e2132.full">http://n.neurology.org/content/94/20/e2132.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 37 articles, 12 of which you can access for free at: <a href="http://n.neurology.org/content/94/20/e2132.full#ref-list-1">http://n.neurology.org/content/94/20/e2132.full#ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/94/20/e2132.full##otherarticles">http://n.neurology.org/content/94/20/e2132.full##otherarticles</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Parkinson's disease/Parkinsonism <a href="http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism">http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>